MA52556A - Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique - Google Patents

Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique

Info

Publication number
MA52556A
MA52556A MA052556A MA52556A MA52556A MA 52556 A MA52556 A MA 52556A MA 052556 A MA052556 A MA 052556A MA 52556 A MA52556 A MA 52556A MA 52556 A MA52556 A MA 52556A
Authority
MA
Morocco
Prior art keywords
hydroxybenzoyl
glp
agonist
amino
salt
Prior art date
Application number
MA052556A
Other languages
English (en)
Other versions
MA52556B1 (fr
Inventor
Simon Bjerregaard
Water Jorrit Jeroen
Sassene Philip Jonas
Rahbek Ulrik Lytt
Andreas Vegge
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA52556A publication Critical patent/MA52556A/fr
Publication of MA52556B1 publication Critical patent/MA52556B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA52556A 2018-05-07 2019-05-06 Compositions solides comportant un agoniste glp-1 et du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate MA52556B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18171046 2018-05-07
EP19720693.1A EP3790575B1 (fr) 2018-05-07 2019-05-06 Compositions solides comportant un agoniste glp-1 et du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate
PCT/EP2019/061502 WO2019215063A1 (fr) 2018-05-07 2019-05-06 Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique

Publications (2)

Publication Number Publication Date
MA52556A true MA52556A (fr) 2021-03-17
MA52556B1 MA52556B1 (fr) 2025-09-30

Family

ID=62134107

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52556A MA52556B1 (fr) 2018-05-07 2019-05-06 Compositions solides comportant un agoniste glp-1 et du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate

Country Status (25)

Country Link
US (1) US11622996B2 (fr)
EP (2) EP3790575B1 (fr)
JP (2) JP7164628B2 (fr)
KR (2) KR102835312B1 (fr)
CN (1) CN112153979A (fr)
AR (1) AR115283A1 (fr)
AU (2) AU2019264783B2 (fr)
BR (1) BR112020021717A2 (fr)
CA (1) CA3097944A1 (fr)
CL (1) CL2020002797A1 (fr)
CO (1) CO2020014570A2 (fr)
ES (1) ES3041298T3 (fr)
HR (1) HRP20251112T1 (fr)
HU (1) HUE073123T2 (fr)
IL (2) IL312620A (fr)
MA (1) MA52556B1 (fr)
MX (1) MX2020011308A (fr)
MY (1) MY206098A (fr)
PE (1) PE20211794A1 (fr)
PH (1) PH12020551691A1 (fr)
PL (1) PL3790575T3 (fr)
RS (1) RS67212B1 (fr)
SG (1) SG11202009978WA (fr)
TW (1) TWI829687B (fr)
WO (1) WO2019215063A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
WO2021089752A1 (fr) * 2019-11-07 2021-05-14 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp-1, un inhibiteur de sglt2 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino) caprylique
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
CN115461044B (zh) * 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
WO2023065231A1 (fr) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Administration orale d'agents thérapeutiques
AR129270A1 (es) 2022-05-10 2024-08-07 Novo Nordisk As Profármacos y usos de los mismos
IL317317A (en) * 2022-07-08 2025-01-01 Novo Nordisk As Highly potent ISVD compounds capable of replacing FVIII(A)
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
CN120435491A (zh) 2022-12-22 2025-08-05 诺和诺德股份有限公司 胰淀素受体激动剂
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
WO2025056575A1 (fr) * 2023-09-11 2025-03-20 Novo Nordisk A/S Anticorps anti-domaine il-6
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
ATE234625T1 (de) * 1994-12-23 2003-04-15 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
WO1999043706A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives d'analogues de glp-1
EP1061946B1 (fr) 1998-02-27 2004-04-28 Novo Nordisk A/S Derives de glp-1 avec une teneur de structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
JP2002524514A (ja) * 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
JP2002542183A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 成形可能な乾燥した医薬製剤
WO2001092206A1 (fr) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Procede de preparation de salicylamides
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
CN1787830A (zh) * 2003-05-14 2006-06-14 爱密斯菲尔科技公司 用于传送肽yy和pyy激动剂的组合物
BRPI0411165A (pt) * 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
BR122019021416A2 (fr) 2003-09-19 2019-12-21
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
EP1696962A2 (fr) 2003-12-18 2006-09-06 Novo Nordisk A/S Nouveaux analogues glp-1 lies a des agents de type albumine
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20070135338A1 (en) 2004-03-31 2007-06-14 Karyn O'neil Human GLP-1 mimetibodies, compositions, methods and uses
CN1968919A (zh) * 2004-04-16 2007-05-23 爱密斯菲尔科技公司 用于递送活性剂的8－（2－羟基苯氧基）辛基二乙醇胺和其盐
JP2007536268A (ja) * 2004-05-06 2007-12-13 エミスフェアー・テクノロジーズ・インク 固体剤形の湿性ヘパリン
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CA2572770A1 (fr) 2004-07-08 2006-01-19 Novo-Nordisk A/S Marquages de prolongation de polypeptide
MX2007000510A (es) * 2004-07-12 2007-03-29 Emisphere Tech Inc Composiciones para suministrar peptido yy y agonistas de pyy.
WO2006037810A2 (fr) 2004-10-07 2006-04-13 Novo Nordisk A/S Composes de glp-1 a action prolongee
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
DK1831252T3 (da) 2004-12-22 2009-10-05 Lilly Co Eli GLP-1 analog fusionsproteinformuleringer
US20070128193A1 (en) 2004-12-22 2007-06-07 O'neil Karyn T GLP-1 agonists, compositions, methods and uses
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
EP1968645A4 (fr) 2005-12-22 2009-11-04 Centocor Ortho Biotech Inc Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
WO2007121318A2 (fr) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Préparations destinées à l'administration d'insuline
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
WO2008011446A2 (fr) 2006-07-18 2008-01-24 Centocor, Inc. Mimétiques de la glp-1 humaine, compositions, procédés et utilisations
WO2008019143A2 (fr) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc Utilisation d'exendines et d'agonistes d'exendines et d'agonistes du récepteur glp-1 pour modifier la dimension de particule et la composition de sous-classe de lipoprotéines
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
WO2008023050A1 (fr) 2006-08-25 2008-02-28 Novo Nordisk A/S Composés d'exendine-4 acylée
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
US20100069410A1 (en) 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
EP1980245A1 (fr) 2007-04-11 2008-10-15 Cephalon France Composition pharmaceutique bicouche lyophilisée et ses procédés de fabrication et d'utilisation
US20100080829A1 (en) 2007-04-11 2010-04-01 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
GB0707662D0 (en) * 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
WO2009030771A1 (fr) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides dérivés avec a-b-c-d et utilisation thérapeutique de ceux-ci
EP2190872B1 (fr) 2007-09-05 2018-03-14 Novo Nordisk A/S Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
JP2011506442A (ja) 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
JP2009274983A (ja) 2008-05-14 2009-11-26 Kowa Co ニコチン酸アミドを含有する経口医薬組成物
EP2303226B1 (fr) 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Libération prolongée d'exenatide et autres polypeptides
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
SI2341905T2 (sl) 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
US8425968B2 (en) 2009-06-19 2013-04-23 Pepsico., Inc. Beverage preservative system containing pimaricin-cyclodextrin complex
US20120065255A1 (en) 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011106378A2 (fr) 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Thérapie orale à la vitamine b12
WO2011109784A1 (fr) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation de conjugués peptidiques insulinotropiques
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2012177929A2 (fr) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Procédés pour traiter le diabète avec des formulations à libération prolongée d'agonistes de procédé glp-1
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
HRP20181447T1 (hr) * 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es) * 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
KR102272671B1 (ko) * 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN103405753B (zh) 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
TW201609798A (zh) 2013-12-13 2016-03-16 賽諾菲公司 Ｅｘｅｎｄｉｎ－４胜肽類似物
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
US20180263915A1 (en) 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
CN107708667A (zh) 2015-06-16 2018-02-16 太阳医药高级研发有限公司 长效利拉鲁肽组合物
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
WO2018065634A1 (fr) 2016-10-07 2018-04-12 Cyprumed Gmbh Compositions pharmaceutiques pour l'administration par voie nasale de médicaments de type peptide ou protéine
WO2018076074A1 (fr) 2016-10-31 2018-05-03 Suda Ltd Administration de principes actifs par voie muqueuse
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
MX2020010505A (es) 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Also Published As

Publication number Publication date
MY206098A (en) 2024-11-28
EP3790575A1 (fr) 2021-03-17
US20230087952A1 (en) 2023-03-23
JP7164628B2 (ja) 2022-11-01
IL277857B2 (en) 2024-10-01
MX2020011308A (es) 2020-11-18
WO2019215063A8 (fr) 2020-07-02
AR115283A1 (es) 2020-12-16
KR20250111399A (ko) 2025-07-22
EP3790575C0 (fr) 2025-07-30
PE20211794A1 (es) 2021-09-09
US20210236601A1 (en) 2021-08-05
IL277857B1 (en) 2024-06-01
ES3041298T3 (en) 2025-11-11
RS67212B1 (sr) 2025-10-31
TW202015722A (zh) 2020-05-01
CN112153979A (zh) 2020-12-29
HRP20251112T1 (hr) 2025-11-07
IL277857A (en) 2020-11-30
IL312620A (en) 2024-07-01
SG11202009978WA (en) 2020-11-27
CL2020002797A1 (es) 2021-02-19
BR112020021717A2 (pt) 2021-01-26
TWI829687B (zh) 2024-01-21
AU2025204852A1 (en) 2025-07-24
US11622996B2 (en) 2023-04-11
WO2019215063A1 (fr) 2019-11-14
JP2021523149A (ja) 2021-09-02
EP4674479A3 (fr) 2026-01-28
PL3790575T3 (pl) 2025-11-17
PH12020551691A1 (en) 2021-07-19
MA52556B1 (fr) 2025-09-30
AU2019264783A1 (en) 2020-12-10
AU2019264783B2 (en) 2025-04-03
KR102835312B1 (ko) 2025-07-18
EP4674479A2 (fr) 2026-01-07
CO2020014570A2 (es) 2021-03-08
CA3097944A1 (fr) 2019-11-14
KR20210008353A (ko) 2021-01-21
JP7529743B2 (ja) 2024-08-06
JP2022191439A (ja) 2022-12-27
EP3790575B1 (fr) 2025-07-30
HUE073123T2 (hu) 2026-01-28

Similar Documents

Publication Publication Date Title
MA53076A (fr) Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique
MA52556A (fr) Compositions solides comprenant un agoniste de glp-1 et un sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylique
IL289504A (en) Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MA51082A (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
HUE036066T2 (hu) GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
HRP20251042T1 (hr) Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild)
MA46044A (fr) Compositions de nettoyage comprenant un acide aminé et leurs procédés d'utilisation
EP3903827A4 (fr) Utilisation d'une molécule de couplage de rifamycine-quinolizidone et de sel pharmaceutiquement acceptable de celle-ci
EP3414256A4 (fr) Sel d'amine de l'acide obéticholique
IL289505A (en) Solid preparations comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid
EP3839045A4 (fr) Mutant d'acide aminé déshydrogénase et application associée
EP3911148A4 (fr) Compositions micellaires solides d'acides cannabinoïdes
EP3762503A4 (fr) Séparation d'acides aminés basiques
EP3666893A4 (fr) Déshydrogénase d'acide aminé type d
EP3520795A4 (fr) Composition comprenant une combinaison d'un analogue de la trh et d'acide arundique, et sel pharmaceutiquement acceptable de l'acide arundique
EP4053109A4 (fr) SEL D'ADDITION D'ACIDE DE RÉGULATEUR DE RORy
GB201917723D0 (en) Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
EP3843779A4 (fr) Agents d'appauvrissement en acides aminés en guise d'agents antiprolifératifs
HK40067692A (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP4526394A4 (fr) Stabilisation de compositions aqueuses acides aminés-hcl
DK3989999T3 (da) Ny sammensætning indeholdende forgrenede aminosyrer
IT201900025066A1 (it) Composto di formula (i) e unita' sensoristica che lo comprende